Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of CUVPOSA™ (glycopyrrolate), the first liquid treatment for patients ages 3-16 who suffer from chronic severe drooling associated with neurologic conditions such as cerebral palsy. CUVPOSA™ was designated an Orphan Drug by the FDA.
Creating memories for families by sharing information relating to children and parents with regard to activities, products, school, home and more.
Shionogi's CUVPOSA receives FDA approval for treatment of chronic severe drooling
- Login or register to post comments
- Feed: Pediatrics News Feed
- Original article